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Available online 25 September 2015While anxiety disorders are the brain disorders with the highest prevalence and constitute amajor burden for soci-
ety, a considerable number of affected people are still treated insufﬁciently. Thus, in an attempt to identify potential
newanxiolytic drug targets, neuropeptides have gained considerable attention in recent years. Compared to classical
neurotransmitters they often have a regionally restricted distribution andmay bind to several distinct receptor sub-
types. Neuropeptide Y (NPY) is a highly conserved neuropeptide that is speciﬁcally concentrated in limbic brain
areas and signals via at least 5 different G-protein-coupled receptors. It is involved in a variety of physiological pro-
cesses including themodulation of emotional-affective behaviors. An anxiolytic and stress-reducing property of NPY
is supported by many preclinical studies. Whether NPY may also interact with processing of learned fear and fear
extinction is comparatively unknown. However, this has considerable relevance since pathological, inappropriate
and generalized fear expression and impaired fear extinction are hallmarks of human post-traumatic stress disorder
and a major reason for its treatment-resistance. Recent evidence from different laboratories emphasizes a fear-
reducing role of NPY, predominantly mediated by exogenous NPY acting on Y1 receptors. Since a reduction of
fear expressionwas also observed in Y1 receptor knockoutmice, other Y receptorsmaybe equally important. By act-
ing onY2 receptors, NPYpromotes fear extinction andgenerates a long-termsuppressionof fear, two important pre-
conditions that could support cognitive behavioral therapies in human patients. A similar effect has been
demonstrated for the closely related pancreatic polypeptide (PP)when acting on Y4 receptors. Preliminary evidence
suggests that NPY modulates fear in particular by activation of Y1 and Y2 receptors in the basolateral and central
amygdala, respectively. In the basolateral amygdala, NPY signaling activates inhibitory G protein-coupled
inwardly-rectifying potassium channels or suppresses hyperpolarization-induced I(h) currents in a Y1 receptor-
dependent fashion, favoring a general suppression of neuronal activity. A more complex situation has been de-
scribed for the central extended amygdala, where NPY reduces the frequency of inhibitory and excitatory postsyn-
aptic currents. In particular the inhibition of long-range central amygdala output neurons may result in a Y2
receptor-dependent suppression of fear. The role of NPY in processes of learned fear and fear extinction is, however,
only beginning to emerge, andmultiple questions regarding the relevanceof endogenousNPY anddifferent receptor
subtypes remain elusive. Y2 receptorsmay be of particular interest for future studies, since they are themost prom-
inent Y receptor subtype in the human brain and thus among the most promising therapeutic drug targets when
translating preclinical evidence to potential new therapies for human anxiety disorders.
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Neuropeptide Y (NPY) is a 36 amino acid peptide that belongs to a
family of biologically active peptides comprising NPY, peptide YY
(PYY) and pancreatic polypeptide (PP) (El-Salhy et al., 1982; Tatemoto
et al., 1982). Since they provide bidirectional communication between
gut and brain, they belong to the family of gut–brain peptides (Holzer
et al., 2012). The peptides are translated from the respective mRNAs
as pre-pro-peptides. Their signal peptide targets them to the endoplas-
mic reticulumand is proteolytically removed. The pro-peptides are then
packaged in the Golgi apparatus into large-dense core vesicles and, in
neurons, transported to the axon terminals. Within large-dense-core
vesicles, pro-peptides are proteolytically processed by prohormone
convertases (PC-1 and PC-2), carboxypeptidase E/H and by peptidyl-
glycine alpha-amidating monooxygenase to the mature amidated pep-
tide (NPY1-36). NPY is released upon sustained depolarization together
with classical neurotransmitters by exocytosis (Brakch et al., 1997;
Hokfelt, 1991).
In the peripheral nervous system, NPY is expressed predominantly
in enteric neurons in the adrenal medulla and in postganglionic sympa-
thetic neurons, co-localizing there primarily with noradrenaline and
ATP (Lundberg et al., 1990). However, the majority of NPY is located
within the central nervous system (CNS) where it is considered to be
themost abundant neuropeptide. In the CNS, NPY is expressed predom-
inantly in the cortex, hippocampus, amygdala, basal ganglia and hypo-
thalamus (Fig. 1A and B) (Fetissov et al., 2004; Morris, 1989; Pelletier
et al., 1984). Furthermore, NPY has beendetected in distinct brain nuclei
of the brain stem, including the periaqueductal gray, locus coeruleus
and dorsal raphe (Yamazoe et al., 1985). Using immunohistochemical
markers it has been demonstrated that NPY in the cortex, hippocampus
and amygdala is expressed in GABAergic neurons co-localizing often
with somatostatin (SST) and to a lower extentwith parvalbumin andni-
tric oxide (Karagiannis et al., 2009; McDonald, 1989; Somogyi et al.,
2012; Tricoire et al., 2010). In addition, NPY-like immunoreactivity
(NPY-IR) has been identiﬁed in long ﬁber tracts, such as the corpus
callosum and stria terminalis (Allen et al., 1983; Tasan et al., 2010).
Mechanic transection of the stria terminalis resulted in reduced NPY-
IR in the bed nucleus of the stria terminalis (BNST), basal forebrain
and hypothalamus, suggesting expression of NPY also in projection
neurons (Allen et al., 1984). NPY is generally expressed in dispersedinterneurons (Fig. 1A). However, there are distinct brain nuclei that
consist of a particularly high density of NPY neurons: the arcuate nucle-
us of the hypothalamus (Arc, Fig. 1A), the bed nucleus of the anterior
commissure (BAC, Fig. 2A), the reticular nucleus of the thalamus (RT,
Fig. 2B) (Morris, 1989), and the main intercalated nucleus of the amyg-
dala (Im, Fig. 2C) (Wood et al., 2015).
The other two members of the NPY family, peptide YY (PYY) and
pancreatic polypeptide (PP) are absent from the CNS but are predomi-
nantly expressed in L-cells of the gut and in F-cells of the pancreatic is-
lets, respectively. Upon release, they may act either locally within the
gastrointestinal tract and pancreas or may be transported by the blood
circulation and bind to Y receptors at distinct brain areaswith a partially
open blood–brain barrier, such as the hypothalamus or area postrema
(Holzer et al., 2012).
Physiologically, NPY is involved in a variety of distinct processes,
such as energy homeostasis, appetite, processing of pain, seizure
suppression and importantly also in the modulation of emotional-
affective behaviors (Hokfelt et al., 2008; Lee and Herzog, 2009; Lin
et al., 2004; Loh et al., 2015; Sperk et al., 2007; Vezzani and Sperk,
2004). These effects are mediated by at least 5 different G-protein
coupled receptors (Y1, Y2, Y4, Y5 and y6) (Michel et al., 1998).
While NPY displays equally high afﬁnities for all 5 receptors, PP
preferentially recognizes Y4 receptors, while the cleavage products
PYY3-36 and NPY3-36 bind to Y2 and Y5 receptors. However, in the
CNS the predominant receptors are Y1 and Y2 receptors, which are
distributed throughout the brain with a particular enrichment in
limbic brain areas, such as hippocampus, amygdala, and hypothala-
mus but also in the different layers of the cerebral cortex (Fig. 1C-
F) (Dumont et al., 1993, 1996). It is noteworthy that, although Y1
and Y2 receptors are often expressed in the same brain areas, they
display a highly complementary distribution, probably reﬂecting
the postsynaptic and presynaptic localization of Y1 and Y2 receptors,
respectively (Fig. 1C–F). On the other hand, Y4, Y5 and also y6
receptors are only apparent in deﬁned brain areas, generally
representing a minor fraction of Y receptors in the CNS (Dumont
et al., 1993, 1998; Yulyaningsih et al., 2014).
A considerable amount of literature supports an anxiolytic and
antidepressant-like function of NPY and has been extensively reviewed
previously (Bowers et al., 2012; Gilpin, 2012; Heilig, 2004; Wu et al.,
2011). These effects are predominantly mediated by activation of Y1
Fig. 1. Distribution of NPY, Y1 and Y2 receptors in the mouse brain. (A) Autoradiograph of
NPYmRNAdistribution in a coronal sectionof amouse brain, (B)photomicrographdepicting
NPY-immunoreactivity (NPY IR) on a coronal mouse brain section (arrow indicates the par-
ticularly high expression in the hippocampus and amygdala). (C) Autoradiographs of an in
situ hybridization and (D) receptor binding using [125I] Leu31Pro34 PYY depicting Y1 receptor
mRNA and protein, respectively (note the high levels of Y1mRNA in the dentate granule cell
layer and the corresponding Y1 receptor binding in the molecular layer, suggesting expres-
sion on soma and dendrites). (E) Autoradiograph of an in situ hybridization and (F) receptor
binding for Y2 receptors ([125I] PYY3-36) on coronal mouse brain sections. Note the expres-
sion of Y2mRNA in the granule cell layer andY2 receptor binding in CA3, indicating pre-syn-
aptic localization. Arrows in (E) indicate high Y2 mRNA expression in hippocampus and
central amygdala (black arrows) and moderate expression in the basolateral amygdala
(white arrow). Scale bar 2 mm.
Fig. 2. Dense accumulation of NPY in speciﬁc brain areas in a NPY-GFP mouse.
(A) Photomicrographs of immunohistochemistry for NPY-GFP (NPY-GFP IR) depicting a
dense accumulation of NPY-GFP in the bed nucleus of the anterior commissure (BAC),
(B) in the reticular nucleus of the thalamus (RT) and (C) in the main intercalated nucleus
(Im). All three brain areas contain high-densities of low-level NPY expressing neurons.
Scale bar 200 μm.
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anxiogenic. Furthermore, recent reviews also summarize the role of
NPY in stress-related psychiatric disorders (Enman et al., 2015; Sah
and Geracioti, 2013).
In the present review we will focus on the role of NPY in animal
models of learned fear and fear extinction and related human
pathologies. Furthermore, to provide a tentative framework for the un-
derlying mechanisms, we will summarize the electrophysiological and
neurobiochemical data aswell as the connectivity of NPY and Y receptor
containing neurons speciﬁcally in limbic brain areas that are relevant
for fear learning.2. NPY, fear and depression in humans
2.1. The NPY system in the human brain
Over the past three decades, NPY has been identiﬁed as amajor neu-
rochemical component of the stress response, coordinating cardiovas-
cular, neuroendocrine, immune and metabolic functions (Heilig, 2004;
Rasmusson et al., 2010). Such a functional diversity can only be carried
out by a widespread distribution in the central and peripheral nervous
systems. A considerable overlap in brain NPY-expression was observed
between different species, including the human brain. The highest
levels of NPY-IR and NPY mRNA have been demonstrated in the
human dentate gyrus with somewhat lower expression in the amygda-
la, basal ganglia and cortex (Adrian et al., 1983; Caberlotto et al., 2000).
On the other hand, species differences have been observed regarding
NPY receptor distribution and density (Dumont et al., 1998). In the ro-
dent brain (mouse and rat), Y1 and Y2 receptors are most abundant,
with Y1 receptors being primarily expressed in the superﬁcial layers
of the cerebral cortex (Fig. 1C and D) and in the molecular layer of the
dentate gyrus and Y2 receptors display a particular enrichment in the
strata oriens and radiatum of the hippocampal formation (Fig. 1E and
F) as well as in the septum. In contrast, receptor binding performed on
postmortem human brain tissue revealed an apparent paucity of Y1 re-
ceptor binding sites (determined by [125I] Leu31Pro34-PYY), with nota-
ble expression in the dentate gyrus but relative absence from cortical
areas. Interestingly, considerably higher expression of Y2 receptors (de-
termined by [125I] PYY3-36) were observed in the superﬁcial and middle
layers of the human cortex, two brain areas that are generally populated
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thermore, it was suggested that NPYmRNA co-localizeswith Y2, but not
Y1 receptor mRNA in the human cortex, hippocampus, amygdala and
striatum (Caberlotto et al., 2000), while substantial evidence for a co-
localization of NPY and Y2 receptors in the rodent brain is still lacking
(Stanic et al., 2011; Wood et al., 2015). Although comparing fresh
snap-frozen tissue from rodents with post mortem tissue from human
subjects that was frozen with a delay of up to 23 h may bear potential
pitfalls, the relative abundance of Y2 receptors and the paucity of Y1 re-
ceptors in human brain tissue has to be taken into consideration when
extrapolating the contribution of individual Y receptor subtypes in
fear-related behavior from rodent to human. Similarly, the presence of
NPY in limbic regions of the human brain may indicate a role in emo-
tional processing, but again, translation from localization to function
or from preclinical models to humans is not without caveats.
2.2. Role of NPY in pathological fear in humans — focus on post-traumatic
stress disorder
NPYmay, however, adapt thewhole organism to stressful, potential-
ly life-threatening conditions andmaintain the psychological and phys-
iological integrity, similarly in rodents (Cohen et al., 2012) and humans
(Wu et al., 2013), by orchestrating resilience to traumatic events (Wu
et al., 2013).While most people are resilient to traumatic events and re-
cover within hours or days, some never recover completely or even de-
velop a permanent state of heightened fear and anxiety, commonly
referred to as Post-Traumatic Stress Disorder (PTSD) (Kessler et al.,
2005). PTSD is characterized by emotional numbing and avoidance of
the traumatic memories, hyper-arousal and ﬂashbacks with a tendency
towards fear generalization. Unspeciﬁc cues associated with the initial
traumatic event can then evoke a context-inappropriate fear response
even in the absence of actual danger. The development of PTSD has
been linked to dysfunction of the hypothalamic–pituitary–adrenal
(HPA) axis and the sympathetic nervous system, and both are modulat-
ed by NPY (Heilig, 2004; Hirsch and Zukowska, 2012; Rasmusson et al.,
2010). Thus, investigating inter-individual differences in disease sus-
ceptibility in human patientsmay help to unravel the underlyingmech-
anisms and the relevance of NPY in PTSD. Indeed, it has been suggested
that polymorphisms in the NPY gene predict individual differences in
stress response and emotionality. Thus, genetically induced lower NPY
expression may result in higher emotion-induced activation of the
amygdala (Zhou et al., 2008, but see also Cotton et al. (2009)), develop-
ment of major depression (Mickey et al., 2011), as well as lower NPY
plasma levels (Xu et al., 2012, but see also Nishi et al. (2014)). Further-
more, a functional NPY variation was suggested to cause lower NPY
mRNA expression in the amygdala and reduced cerebrospinal ﬂuid
(CSF)-NPY levels in higher primates exposed to aversive situations
(Lindell et al., 2010). The relevance of NPY levels in CSF and plasma
for emotional processing in the CNS is deﬁnitely limited and probably
reﬂects predominantly sympathetic nervous system activity and release
from the adrenal gland. However, genetic polymorphisms may affect
NPY processing in the CNS and periphery in a similar manner, suggest-
ing that the CSF/plasma levels could parallel an altered NPY system in
the brain.
2.3. Response of NPY plasma levels to sympathetic stimulation, stress, and
post traumatic stress disorder in humans
Since NPY is contained in sympathetic neurons and in the adrenal
medulla together with noradrenaline and adrenaline, respectively,
stress exposuremay also increase NPY plasma levels. For instance, intra-
venous administration of the adrenergic α2-receptor antagonist, yo-
himbine, in healthy subjects was suggested to augment noradrenaline
and NPY release from sympathetic neurons resulting in increased NPY
plasma levels (Rasmusson et al., 1998). Similarly, after exposing healthy
subjects to uncontrollable stress, NPY plasma levels increased togetherwith cortisol and noradrenaline (Morgan et al., 2001; Rasmusson
et al., 2010). As mentioned above, plasma NPYmainly serves as an indi-
cator for sympathetic activity and correlations between plasma and CSF
concentrations are also relatively weak (Baker et al., 2013). NPY in the
plasma may, however, also interact with Y receptors in brain areas
that are partially open to the blood–brain barrier, such as the arcuate
nucleus of the hypothalamus or the area postrema. Since neurons of
the arcuate nucleus project not only to other hypothalamic nuclei but
also to the amygdala and to the BNST (Betley et al., 2013), plasma NPY
may play an indirect role in the integration of emotional, autonomic,
and metabolic functions (Akabayashi et al., 1994; Heilig, 1995). In line
with this, intravenous infusion of NPY decreased HPA-axis activation
resulting in reduced cortisol levels, suggesting that also NPY in the plas-
ma may have important implications for regulating emotional states
(Antonijevic et al., 2000). Compared to healthy controls, PTSD patients
displayed lower NPY levels in the plasma (Rasmusson et al., 2010;
Yehuda et al., 2006) and CSF (Sah et al., 2009, 2014) already under base-
line conditions. Whether these changes are related to the disorder (Sah
et al., 2014) or to an extreme stress exposure per se (Morgan et al.,
2003) remains to be demonstrated. However, NPY levels seem to recov-
er during remission from PTSD (Yehuda et al., 2006) indicating that NPY
may serve as a resilience factor in PTSD or at least as a potential
biomarker.
Taken together, these studies indicate that NPY can act as a stress
buffer in response to traumatic events mainly by reducing noradrener-
gic hyperactivity and that NPY levels loosely parallel the disease course
in PTSD patients. Although PTSD is a complex disease, individual aspects
may be recapitulated in animal models. Thus, Pavlovian fear condition-
ing may mimic the etiology and maintenance of PTSD (“Fear acquisi-
tion”) and may also serve as a model for cognitive behavioral therapy
(“Fear extinction”), reﬂecting the underlying principles of exposure
therapy in human patients (Jovanovic and Ressler, 2010; Milad et al.,
2009). Thus, comparing animalmodelswith the human diseasemay in-
crease our understanding of the biological mechanisms underlying
pathological fear, opening new possibilities of interfering with the dis-
ease course.
3. Neuropeptide Y and pancreatic polypeptide in fear and
fear extinction
3.1. Fear conditioning and extinction
Anxiety is generally described as a diffuse and unpleasant apprehen-
sion of a forthcoming threat involving predominantly an imagined, po-
tential danger (Barlow, 2002). In contrast, fear is considered to be an
emotional response towards a clearly identiﬁable, real and immediate
threat that is essentially based on previous learning processes (Marks,
1987). However, anxiety and fear are intimately connected, may cause
each other and human anxiety disorders are characterized by variable
degrees of both. Experimentally, fear and anxiety can be studied by dif-
ferent behavioral paradigms. Fear learning involves distinct learning
processes requiring the disentanglement of learning and memory
from the accompanying emotional aspects. However, fear can be inves-
tigated in a highly controlled setting consisting of clearly deﬁned con-
secutive phases. Thus, fear is generally investigated by Pavlovian fear
conditioning: a simple form of associative learning that involves the re-
petitive pairing of an initially neutral stimulus (conditioned stimulus,
CS), such as a tone with an aversive stimulus, typically a mild electric
foot shock (unconditioned stimulus, US) (LeDoux, 2000). The successful
fear learning is then measured by the emotional response (freezing be-
havior, alterations in blood pressure and heart rate or increased skin
conductance) after exposure to the tone alone. A consecutive fear ex-
tinction training consisting of repetitive presentations of the CS in the
absence of a foot-shock usually results in a reduction of the fear re-
sponse (an overviewof the fear and extinction pathway in the amygdala
is depicted in Fig. 3B and Fig. 4 and respective ﬁgure legends). Extinction
Fig. 3.High levels of NPY in the fear circuitry of the amygdala. (A) Photomicrograph depicting NPY-IR in a coronal section of a mouse brain depicting strong labeling of NPY-NPY IR in the
basolateral (BLA) and central amygdala (CEA), (B) highermagniﬁcation of NPY-IR in the amygdalawith arrows indicating the fear circuit: (1) thalamic and cortical inputs are transmitting
fear related stimuli to neurons of the lateral amygdala (2), which are in turn projecting the BLA (3) that is known for its reciprocal connectionswith the prefrontal cortex (prelimbic: fear;
infralimbic: extinction) and hippocampus (context fear). Projections from the lateral amygdala (2) are targeting, via dorsomedial intercalated neurons (dashed arrow), the centrolateral
amygdala (CEl, 4) and BLA neurons project directly (fear neurons) or indirectly (extinction neurons) via themain intercalated nucleus (Im, 5) to the centromedial amygdala (CEm, 6), the
main output nucleus of the amygdalawith efferent connections to the bed nucleus of the stria terminalis, hypothalamus and brain stem. (C) Highermagniﬁcation depicting NPY-IR in the
BLA, (D) CEl and (E) CEm. Note the dense labeling of thin axons in the BLA, faint ﬁber labeling in the CEl and distinct axons with big varicosities in the CEm (black arrows). Scale bars in A:
2 mm, B: 200 μm and C-E: 20 μm.
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the underlying principle of human exposure therapy (Quirk and
Mueller, 2008). The experimental properties of fear and extinction
learning are highly controlled and largely independent of the prevailing
motivational state of the tested subject. An advantage of these control-
lable settings is that different drugs or molecules that are suspected to
modify the processing of fear conditioning and extinction can be applied
in a controlled manner during the different experimental phases. Thus,
the obtained results may provide valuable information relevant for
treatment of human anxiety disorders.
3.2. Role of NPY in fear conditioning and extinction
A role of NPY in emotionalmemory processeswasﬁrst postulated by
Flood et al. (1987) whereby NPY affected learning and memory in a
complex time and dose-dependent manner with an overall enhance-
ment of retention in a T-maze foot-shock avoidance and a step-down
passive avoidance training in mice (Flood et al., 1987). This effect was
likely mediated by Y2 receptors in the dorsal but not in the ventral hip-
pocampus (Cleary et al., 1994; Flood et al., 1989; Flood and Morley,
1989). However, since the test settings were rather complex, a clear
conclusion regarding the effect of NPY on memory in general and the
isolation of an anxiolytic and possibly also fear-reducing component is
rather difﬁcult to draw.
Early evidence that NPY modiﬁes, in particular, fear learning comes
from thework of Broqua et al. (1995). In this study, the authors suggested
that intracerebroventricular (icv) injections of NPY and PYY inhibited
fear-potentiated startle in rats. Since the Y1 receptor-preferring agonist
Leu31Pro34-NPY produced a similar response as NPY, the effects were
likely mediated by Y1 receptors. However, NPY2-36 (a mixed Y2/Y5agonist) but not NPY13-36 (a more speciﬁc Y2 agonist) was also effective,
suggesting the involvement of additional Y receptors (Broqua et al.,
1995). All drugs were applied icv, indicating that the involved brain
areas may be close to the ventricular system, however, an exact localiza-
tion of this effect is still open.
Furthermore, transgenic rats over-expressing NPY displayed absent
fear suppression in a punished drinking test and impaired spatial memo-
ry acquisition in theMorriswater maze, suggesting a potential amnestic
effect of NPY on emotional learning processes (Thorsell et al., 2000). Al-
ternatively, a higher stress-buffer may drive NPY over-expressing rats
to tolerate increased numbers of punished drinking episodes. Neuro-
chemical alterations included a marked increase of NPY mRNA in the
CA1 of these rats that was accompanied by a down-regulation of Y1 re-
ceptors but not of Y2 receptor binding sites in all hippocampal subﬁelds.
These data shift the Y2 receptor in the dorsal hippocampus into focus as a
possible candidate for suppression of spatial and potentially also fear-
related memories. On the other hand, germ-line over-expression of a
neuropeptide (i.e. NPY) may alter the establishment of synaptic contacts
during pre- and postnatal development leading to additional changes
that may have remained undetected in this study.
Using contextual and cued fear conditioning, Karlsson et al. (2005)
suggested that icv administration of NPY prior to training reduced con-
text (0.5 nmol) and cued (1 nmol) freezing behavior in C57BL/6J mice
when tested 24 h later under drug free conditions (Karlsson et al.,
2005). Although post-US/CS freezing levels, examined immediately
after fear acquisition were reduced by approximately 20%, this change
was not signiﬁcant. However, it may indicate that the action of NPY al-
ready inﬂuenced the acquisition of fear. Cued fear conditioning depends
predominantly on the amygdala, whereas contextual fear is also modu-
lated by the hippocampal formation in conjunction with the basolateral
Fig. 4. Proposed fear circuit in the amygdala and potential interaction points of identiﬁed NPY
neurons. Cortical and thalamic projections conveying somatosensory (US) and auditory (CS) in-
formation are targeting the lateral amygdala (LA), a major location of initial synaptic plasticity.
SST/NPY/GABAneuronsmay inhibit pyramidal neurons by activation of Y1 andY2 receptors re-
ducing CS-related activation and fear learning. Similarly SST/NPY neurons in the basolateral nu-
cleus (BLA)may have additional Y1 receptor-dependent inhibiting effects. The role of NPYergic
afferent and efferent projections of the basolateral complex (LA and BLA) is not yet clear. Fear-
related stimuli reach the central amygdala (CEA) also via mediodorsal intercalated neurons
(ITCd to the centrolateral subdivision, CEl) or directly via projections from the BLA to the
centromedial subdivision (CEm).NPYneuronsmaymodulate afferent andefferent signals local-
ly in theCElor via inhibitory connectionsbetweenCEl andCEm,probablybyY2 receptors.How-
ever, the main processing occurs in the CEm (expressing Y1 and Y2 receptors) by (1) local
inhibitory SST/NPY/GABA neurons, (2) by NPY/GABA afferents originating from the BNST and
(3) by NPY axon terminals originating from neurons of the main intercalated nucleus (Im).
The latter projection consisting ofNPY/D1R/GABAneurons in the Im is considered to play an es-
sential role in fear extinctionbyprovidingamarked increase in feed-forward inhibition fromthe
BLA to theCEm. Lastly, efferents from theCEmmaybe furthermodulatedbyNPYalong the stria
terminalis (st) or even in the bed nucleus of the stria terminalis (BNST), both by local interneu-
rons and by bi-directional projections connecting the CEm with the BNST. (AStr,
amygdalastriatal transition zone, En, entorhinal cortex, Pir, pririfrom cortex, BF, basal forebrain,
CEc, capsular subdivision of the central amygdala nucleus).
Table 1
Summary of the role of NPY and Y receptors in different phases of fear conditioning and extinc
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Context fear
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Reduction,
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116 R.O. Tasan et al. / Neuropeptides 55 (2016) 111–126amygdala (BLA) (Maren et al., 2013; Pape and Pare, 2010). As the icv ap-
plication of NPY precludes a clear anatomical correlation, further studies
are needed to elucidate the fear-reducing function of NPY in different
limbic brain areas.
A fear-reducing effect was corroborated by an NPY-induced sup-
pression of tachycardia during fear recall in an auditory fear condition-
ing paradigm in mice. The CS-induced tachycardia was also reduced by
icv injection of the Y1 receptor agonist [D-Arg25]hNPY while the Y1 re-
ceptor antagonist BIBO 3304 (icv) was able to block the effects of icv
NPY injections. These results indicate that tachycardia induced by aver-
sive stimuli can be suppressed by exogenous NPY, probably by a Y1
receptor-dependent mechanism (Tovote et al., 2004). The involvement
of other Y receptors and the role of endogenousNPYwere, however, not
addressed in this study.
The above ﬁndings are in agreement with the work of Gutman et al.
(2008) testing the effect of NPY in the fear potentiated-startle paradigm
in rats. They suggested that exogenously appliedNPY, either icv or local-
ly in the BLA, reduces the expression of conditioned fear, but not when
injected locally into themedial amygdala (MEA). Interestingly, injection
of the Y1 receptor antagonist BIBO 3304 into the BLA had no effect, sug-
gesting that endogenousNPY in the BLA has no fear-reducing properties
in this paradigm.
Furthermore icv injection of NPY facilitated the extinction of fear-
potentiated startle while injection of the Y1 antagonist BIBO 3304
alone into the BLA blocked fear extinction (Gutman et al., 2008). Collec-
tively, these data suggest that NPY reduces the expression of fear prob-
ably independent of Y1 receptors or alternatively that only exogenous
application of NPY may reduce fear expression. On the other hand, en-
dogenous NPY may facilitate fear extinction learning and recall likely
by activation of Y1 receptors in the BLA (see Table 1).
In addition to classical pharmacological manipulations, genetic dele-
tions of speciﬁc receptors or combining pharmacology and receptor
knockout mice are attractive alternative strategies for studying the
role of NPY in fear processing. Interestingly, fear conditioning experi-
ments performed in Y1 receptor knockout (Y1KO) mice do not neces-
sarily support a central role of Y1 receptors in the modulation oftion.
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117R.O. Tasan et al. / Neuropeptides 55 (2016) 111–126conditioned fear. More speciﬁcally, Y1KO mice did not display altered
fear expression during fear acquisition and during context or cue-
related fear recall, as consistently reported by independent groups
(Fendt et al., 2009; Karlsson et al., 2008; Verma et al., 2012). This may
be explained by the irrelevance of endogenous NPY, suggested by
Gutman et al. (2008) or by the involvement of other Y receptors. On
the other hand, germ-line deletion of Y1 receptors may provoke
adaptations during pre- and postnatal developmentmasking a potential
role of Y1 receptors. It is therefore important to mention that the fear-
reducing effect of intra-amygdala injections of NPY was neither
recapitulated by application of the speciﬁc Y1 receptor agonists Y-28
(Des-AA11–18 [Cys7,21, d-Lys9 (Ac), d-His26, Pro34]-NPY) and Y-36 ([d-
Arg25, d-His26]-NPY) nor blocked by concomitant injections of theY1 re-
ceptor antagonist BIBO 3304 in mice. Consequently, injection of NPY
into the amygdala of Y1KO mice still produced a robust decrease in
fear expression, suggesting the involvement of other NPY receptors in
the amygdala and/or other brain areas in the modulation of learned
fear behavior (Fendt et al., 2009).
The role of NPY in contextual fear conditioning and extinction was
investigated by icv injections of NPY or the Y1 receptor-preferring ago-
nist Leu31Pro34-NPY during context fear acquisition, consolidation and
extinction (Lach and de Lima, 2013). Low doses of NPY (3 pmol) and
Leu31Pro34-NPY (1 pmol) were selected to avoid confounding factors
such as altered locomotor activity or reduced states of anxiety. NPY as
well as Leu31Pro34-NPY inhibited freezing behavior when administered
icv in the acquisition or consolidation phase. These effects were blocked
by pretreatmentwith the Y1 receptor antagonist, BIBO 3304, suggesting
a suppression of contextual fear consolidation by a Y1 receptor-
mediated mechanism. Interestingly, when injected in the extinction
phase, only NPY but not Leu31Pro34-NPY reduced contextual freezing
(Lach and de Lima, 2013). These results demonstrate a robust fear-
inhibiting effect of exogenous NPY on contextual fear conditioning in
rats, a response that is mediated, at least in part, by Y1 receptors (see
Table 1). The fact that only NPY, but not a Y1 receptor agonist reduced
fear during extinction learning, however, suggests again an interplay
with additional Y receptors. As contextual fear conditioning is depen-
dent on hippocampal processes, these data suggest that NPY may have
distinct functions mediated by different receptors depending on the
brain areas targeted. However, as the data were obtained by icv injec-
tions, amore detailed investigation taking into account different speciﬁc
injection sites is still required.
Recent evidence concerning the role of the different Y receptors
comes from the experiments of Verma et al. (2012) by investigating
KOmice lacking NPY and different Y receptors in a differential fear con-
ditioning and extinction paradigm (Verma et al., 2012). NPYKO mice
displayed dramatically accelerated acquisition and an increased expres-
sion of CS-induced conditioned fear. On the other hand, Y1KO mice ex-
hibited only a modestly accelerated fear acquisition, similar to the
changes described by Fendt et al. (2009), whereas Y2KOmicewere sim-
ilar to controls. Interestingly, the strong phenotype seen in NPYKOmice
was only reproduced in mice lacking both Y1 and Y2 receptors. In addi-
tion, NPYKOmice displayed impaired fear extinction. This behavior was
recapitulated again only in Y1/Y2 receptor double KO mice (see Table
1). These data indicate that both, Y1 and Y2 receptors are acting syner-
gistically to reduce the acquisition and expression of conditioned fear
while on the other hand promoting fear extinction. It also suggests
that postsynaptic Y1 and presynaptic Y2 receptors serve a similar pur-
pose in processes of conditioned fear and that theymay in fact compen-
sate for each other.
Furthermore, an important ﬁnding from these experiments (Verma
et al., 2012) was the inability of Y2KO mice to differentiate between
two conditioned auditory stimuli, one that was repetitively paired
with an unconditioned stimulus (CS+) and a second one that was
never paired (CS−). The inability to discriminate fear-related stimuli
from similar but innocuous stimuli points towards a generalization of
conditioned fear. In fact, activation of Y2 receptors may counteractsuch generalization tendencies. Importantly, generalized fear is a phe-
nomenon characteristic for certain types of human anxiety disorders,
such as PTSD, and a main reason for the difﬁculty to achieve long-
term suppression of fear by psychotherapy. Thus, further studies are
needed to address a possible role of Y2 receptors in preventing fear gen-
eralization and to identify the involved neuronal networks.
Interestingly, the fear-reducing effect of NPY reported by Gutman
et al. (2008) was bigger when NPY was applied icv compared to intra-
BLA injections and was probably not purely Y1 receptor-mediated.
These data indicate a contribution of other Y receptors and/or additional
brain areas, as suggested by the experiments of Lach and De Lima
(2013). Evidence supporting a role of Y2 receptors in learned fear was
provided by a recent study demonstrating that viral-vector-mediated
local over-expression of the Y2-preferring agonist NPY3-36 in the central
amygdala reduces the expression of conditioned fear and promotes fear
extinction (Verma et al., 2015b). Importantly, peripheral injection of the
brain-penetrant Y2 receptor antagonist JNJ-31020028 blocked the fear–
reducing and extinction-promoting effect of viral vector-induced over-
expression of NPY3-36. In line with this, site-speciﬁc local deletion of
Y2 receptors in the CEA of conditional Y2 receptor KO mice increased
the expression of conditioned fear and delayed fear extinction (see
Table 1), suggesting also a role of endogenous NPY acting on Y2 recep-
tors (Verma et al., 2015b). In this regard it is important to mention
that local over-expression of NPY3-36 in the CEA also produced a perma-
nent suppression of conditioned fear as evidenced by reduced sponta-
neous recovery (re-emergence of fear over time) and re-instatement
of extinguished fear (re-emergence of fear by stress exposure). Both pa-
rameters, spontaneous recovery and re-instatement, were, however, in-
creased when the mice were pre-treated with ip injections of the Y2
receptor antagonist JNJ-31020028 before extinction training (Verma
et al., 2015b). These ﬁndings have important implications for the trans-
lation of experimental data into clinics. In particular, the labile nature of
fear extinction memories in general, and the frequently observed tran-
sient effect of exposure therapy in human patients constitute a limiting
factor for successful treatment of human anxiety-disorders. A limitation
of the study was, however, the long-term over-expression and deletion
of NPY3-36 and Y2 receptors, respectively that may have triggered adap-
tations actually responsible for the altered fear behavior. Thus, future
studies combining acute local drug injections and Y receptor KO mice
may shed more light on the role of Y2 receptors in the modulation of
conditioned fear.
Most recently, Vermaet al. (2015a,c), also demonstrated an important
role of Y4 receptors in the extinction of fear. In the central nervous sys-
tem, Y4 receptors are expressed in speciﬁc brain areas, such as the hypo-
thalamus and brain stem (Tasan et al., 2009). They are targeted by PP
originating from F-cells of the pancreas. Verma et al. (2015) subjected
Y4KO mice to a differential fear conditioning paradigm followed by con-
textual and cued fear testing and fear extinction. Importantly,while Y4KO
mice displayed unchanged fear acquisition and recall, the extinction of
contextual and cued fear was signiﬁcantly delayed or completely im-
paired, respectively (see Table 1). Interestingly, the impaired fear extinc-
tion was associated with a loss of synaptic plasticity in an amygdala
microcircuit that was rescued by short-term fasting (Verma et al.,
2015c). In fact, also NPY can activate Y4 receptors in the CNS and NPY
may even be the predominant ligand. However, in a follow-up study
Verma et al. (2015a) demonstrated that peripheral injection of a long-
acting Y4 receptor agonist speciﬁcally promoted fear extinction under
fasted but not under fed conditions (Verma et al., 2015a). These data
highlight the close relationship between fear and feeding and put, in par-
ticular, gut-brain related peptides, such as NPY, PYY and PP, into focus for
adapting emotional behaviors to restore internal homeostatic balance.
An interesting and novel strategy of how to interfere with the NPY
system was recently provided by Canneva et al. (2015). In their study,
the group investigated functionally deﬁcient dipeptidylpeptidase IV
(DPP4) congenic rats in Pavlovian fear conditioning and extinction
(Canneva et al., 2015). DPP4 is involved in the degradation of NPY, but
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of fearwas unchanged, short-term fear extinctionwas facilitated inmu-
tant rats. This was associated with altered NPY levels in the CSF and re-
duced mRNA expression in the amygdala for Y1, Y2 and Y5 receptors
but not of NPY itself. The extent to which CSF or plasma levels reﬂect
the conditions in the CNSmay be questionable and is still under debate.
However, the reductions in Y1, Y2 and Y5mRNA levels in the amygdala
indeed suggest an altered NPY turnover. Importantly, prolonged and
high NPY levels may be one explanation for the facilitated fear extinc-
tion. Since these rats harbor a germ-line mutation, adaptations during
embryonic or postnatal development may be equally plausible. In addi-
tion, DPP4 has broad substrate speciﬁcity and NPY is only one of several
potential substrates. Importantly, DPP4 inhibitors are already approved
drugs for treating type 2 diabetes. Thus, this potentially attractive ap-
proach warrants further studies to demonstrate that fear processing
may be indeed modulated by interfering with degradation enzymes
for NPY.
Taken together, the above-mentioned experimental data emphasize
the involvement of multiple Y receptors in the modulation of condi-
tioned fear, and more speciﬁcally they highlight the importance of Y2
and Y4 receptors as important partners of Y1 receptors in the extinction
of learned fear (see Table 1). The role of Y5 receptors as an additional
target has been discussed in many of the above-mentioned studies,
however, experimental data supporting a role of Y5 receptors in condi-
tioned fear are still lacking.
Local injections of NPY suggest that the resulting suppression of fear
is mediated at least in part in the BLA. The role of endogenous NPY act-
ing through Y1 receptors in the suppression of fear is, however, still not
convincingly deﬁned. On the other hand, experiments using local injec-
tions of AAV vectors suggest that Y2 receptors in the CEA suppress fear
expression while promoting fear extinction. Different brain structures,
such as amygdala and hippocampus, are distinctly involved in fear and
extinction learning and NPY may interfere there with multiple path-
ways and receptors. However, only 3 studies have used site-restricted
injections into the amygdala (Fendt et al., 2009), BLA (Gutman et al.,
2008) and CEA (Verma et al., 2015b). As most of the other studies
employed icv injections, the role of NPY in other fear-relevant brain
areas is essentially unknown. It becomes more and more apparent
that apart from Y1 receptors, also other Y receptors, and in particular
Y2 receptors, are involved in fear conditioning and extinction. A wealth
of literature suggests an anxiolytic action of postsynaptic Y1 receptors
and an anxiogenic-like action after activating presynaptic Y2 receptors.
This concept may be questioned, since anxiolysis and improved stress-
coping abilities were lost after backcrossing Y2KO mice to a C57BL/6J
background (Tschenett et al., 2003; Zambello et al., 2011). Overall, the
evolutionary utility of an anxiolytic neuropeptide that essentially acts
as a stress buffer and reduces anxiety by one receptor while at the
same time increasing anxiety by another receptor is difﬁcult to recon-
cile. Under physiological conditions, endogenous NPY is released and
will activate all available Y receptors in a similar fashion. Regarding
fear and fear extinction, it rather seems that individual Y receptor sub-
types exhibit a high degree of synergy collectively directed towards a
reduction of fear expression. In particular, Y2 receptors in the CEA
may adapt inhibitory and excitatory afferents originating from diverse
extinction-related brain areas, including the BLA and the main interca-
lated nucleus, but also cortical structures. Clearly further studies are
needed to elucidate those amygdala inputs that are modulated by NPY
and Y2 receptors.3.3. The role of NPY and its receptors in spatial learning
When looking at the impact of a neuromodulator on emotional
learning processes of fear and fear extinction, one has to consider also
its activity in memory formation in general or ideally on learning pro-
cesses that are largely independent of emotional components.Among theﬁrst studies investigating the role of NPY onmemory for-
mation and retention were those by Flood and coworkers (Flood et al.,
1989). The authors infused 0.05 to 1 μg (0.03 to 0.5 nmol) of NPY into
the rostral and caudal hippocampus, septum, amygdala, striatum and
thalamus of mice and tested the animals for memory retention of foot
shock avoidance training in a T-maze. NPY improved retention when
injected into the septum or the rostral hippocampus but impaired re-
tention when applied to the caudal hippocampus or amygdala. It had
no effects when injected into the striatum or thalamus (Flood et al.,
1989). Injection of an NPY antibody into the same brain regions pro-
duced opposite effects. Since the injections of NPY or the NPY antibody
were performed after training, NPY interfered probably with the mem-
ory consolidation process. This is also supported by NPY injections 24 h
after training, in which no memory-altering effects were observed. On
the other hand, icv injections of higher doses of NPY (3 and 10 μg)
30 min before testing, impaired short-term memory in a conditioned
discrimination task involving a food reward in rats (Cleary et al.,
1994). The test systems used, however, were relatively complex and in-
cluded components of both, spatial and emotional memory.
Thorsell et al. (2000) developed a transgenic rat-line over-expressing
NPY in particular in the CA1 sector of the hippocampus (see above).
These rats displayed a pronounced impairment in acquisition and poten-
tially also retrieval of spatial memory in theMorriswater maze (Thorsell
et al., 2000), a testing paradigm in which rodents have to ﬁnd a hidden
platform in a water-ﬁlled pool by orienting using external cues
(D'Hooge and De Deyn, 2001). The hippocampus is crucially involved
in spatial memory processes and NPY is contained in numerous
GABAergic interneurons of the dentate gyrus and the hippocampus
proper (Sperk et al., 2007). In line with these results, rats overexpressing
NPY in the hippocampus by injecting locally an adeno-associated viral
vector (AAV-NPY) displayed impaired spatial learning during the acqui-
sition of a two-platform discrimination version of theMorriswatermaze
(Sorensen et al., 2008a). The authors also reported impaired long-term
potentiation (LTP is an electrophysiological correlate of synaptic plastic-
ity associated with learning and memory) in ex vivo hippocampal slices
from AAV-NPY injected rats, while basal neurotransmission appeared
unaffected.
In support of a potential role of Y1 receptors, NPY and the Y1 receptor
agonist [Leu31, Pro34] NPY decreased the latency of colchicine treated rats
to ﬁnd the platform in aMorriswater maze, whereas the Y1 receptor an-
tagonist BIBP3226 produced an opposite effect (Rangani et al., 2012).
Furthermore, a recent study found that peripheral injection the Y2
receptor agonist PYY3-36 (1 and 20 μg/kg) signiﬁcantly prolonged the la-
tency to reach the platform in a matching-to-position version of the
Morriswater maze. Whether peripherally injected PYY3-36 may indeed
enter the brain parenchyma (Nonaka et al., 2003) or target only Y2 re-
ceptors in brain areas that are partially open to the blood–brain barrier
(Dumont et al., 2007) remains to be demonstrated. Furthermore, PYY3-
36 is also a potent activator of Y5 receptors, however, a role of Y5 recep-
tors in emotional or non-emotional learning and memory has not been
addressed so far.
In a complementary approach, Redrobe et al. (2004) tested Y2 re-
ceptor germ-line knockout (Y2KO) mice in a Morris water maze.
While memory acquisition in Y2KOmice was similar to controls, mem-
ory retention, tested on day 5whennoplatformwas present, wasmark-
edly impaired in Y2KOmice (Redrobe et al., 2004). Since spatial learning
and retrieval in theMorriswater maze is largely dependent on the hip-
pocampal circuitry (Rolls, 1999), the authors concluded that hippocam-
pal functions were compromised in Y2KO mice (Redrobe et al., 2004).
Taken together, there is a clear trend towards an impairment of spa-
tial memory consolidation and probably also acquisition and retrieval
by exogenous NPY acting on Y2 receptors. Y2KOmice may have the ad-
vantage that they allow an insight into the action of endogenousNPY on
Y2 receptors. However, the apparent discrepancy between the results
obtained in Y2KO mice and the experiments using pharmacology or
viral vectors, might have several other reasons: 1) permanent lack of
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strated to alter synaptic activity (Wood et al., 2015), 2) differences in ge-
netic background are signiﬁcantly inﬂuencing the testing results of
Y2KO mice in the same behavioral approach (Redrobe et al., 2003;
Tschenett et al., 2003; Zambello et al., 2011), 3) in addition, compared
to semi-aquatic rats, mice have an inborn aversion towards water, and
enforced swimming in the Morris water-maze includes a strong emo-
tional, challenge (D'Hooge and De Deyn, 2001; Harrison et al., 2009).
Thus, interpreting Morris water maze performance in mice as purely
memory-related without considering emotional components may har-
bor several pitfalls.
An approach that should have minimal emotional inﬂuence on
memory performance is the object recognition test. This test is based
on spontaneous, differential exploration of a familiar versus a novel ob-
ject (Ennaceur and Delacour, 1988) and is supposed to reﬂect hippo-
campal, and in particular, cortical processing (Buckmaster et al., 2004;
Clark et al., 2000). Y2KO mice displayed impaired consolidation of ob-
ject recognition memory (6 h) (Painsipp et al., 2008; Redrobe et al.,
2004) whereas short-term memory tested after 1 h was still intact.
However, experiments using NPY pharmacology in this test are yet
not available.
In conclusion, a predominant amnestic-like role of NPY has been
proposed for non-emotional learning. Especially in spatial learning,
NPY may exert a modest inhibitory role on memory consolidation and
retrieval, likelymediated by activation of Y2 receptors in the dorsal hip-
pocampus. Such a memory-impairing function of Y2 receptors may in
part underlie the reduced expression of conditioned fear, however, it
does not entirely explain the extinction-promoting effect of Y2 recep-
tors or the long-term suppression of fear. Thus, even though Y2 recep-
tors seem to interfere with the formation of spatial learning, they also
direct emotional memories towards reduced fear expression.
4. Underlying mechanisms
4.1. Distribution and connectivity of NPY neurons in the amygdala complex
NPY is considered to be themost abundant neuropeptide in the rodent
andhumanbrain. Importantly, high levels are found in the amygdala, hip-
pocampus and cerebral cortex (Fig. 1A and B) (Allen et al., 1983;
Gustafson et al., 1986; Morris, 1989), brain areas that are also fundamen-
tally involved in themodulation of conditioned fear (Pape and Pare, 2010;
Sah et al., 2003). Although the basic organization of the fear/survival cir-
cuit has been well described (LeDoux, 2000; Pare et al., 2004), the rele-
vance of individual neurotransmitters and neuromodulators, such as
NPY, and their effects on local microcircuits are only poorly understood.
Essentially, thalamic and cortical inputs (Fig. 3B-1) target the lateral
amygdala (LA, Fig. 3B-2), where the unconditioned stimulus and the con-
ditioned stimulus converge, generating an initial associative fearmemory.
Furthermore, the BLA (Fig. 3B-3) seems to propagate transitions between
different fear states and also reciprocally connects to the hippocampus
and prefrontal cortex conveying information about fear context and/or
fear extinction memories (Herry et al., 2008). The BLA (Fig. 3B-3) and
LA (Fig. 3B-2) project directly or indirectly, via the intercalated cellmasses
(Fig. 3B-5), to the CEA (Fig. 3B-6), which then forms the main efferent
route of the amygdala complex (Pape and Pare, 2010).
4.1.1. NPY in the basolateral amygdala (BLA)
Since NPY is expressed in neurons of several amygdala nuclei (Fig. 3A
and B), it is ideally positioned to inﬂuence different steps of fear and ex-
tinction processing. The BLA is considered to have a cortex-like structure
consisting of glutamatergic principal neurons (PN) and local GABAergic
neurons providing a constant suppression of PN activity. About 15% of
these GABAergic neurons in the BLA were suggested to be immuno-
positive for NPY and more than 80% of BLA-NPY neurons also express
GABA (McDonald, 1989). According to the expression of immunohisto-
chemical markers for calcium-binding proteins and differentneuropeptides, inhibitory BLA-neurons can be divided into several differ-
ent subpopulations: These include parvalbumin (PV) neurons, somato-
statin (SST) neurons, large cholecystokinin (CCK) neurons and small
bipolar neurons containing various amounts of vasoactive intestinal poly-
peptide (VIP), CCK and calretinin (CR) (McDonald and Mascagni, 2001,
2002). In the BLA, NPY is generally co-expressed in the group of SST neu-
rons,where virtually all NPY cells co-express SST (McDonald, 1989).More
than 80% of these SST/NPYneurons in the BLA form symmetrical synapses
at distal dendrites and dendritic spines of CaMKIIalpha-positive pyrami-
dal neurons and their axon terminals were often seen in close proximity
to asymmetrical (excitatory) synapses (Muller et al., 2007). This conﬁgu-
ration may allow SST/NPY neurons to efﬁciently control the impact of in-
puts to their target cells. Indeed, it has been suggested that during
auditory CS presentation PV-positive neurons inhibit SST neurons of the
BLA, enabling associative fear learning (Wolff et al., 2014). Thus, activa-
tion of SST neurons, and probably also concomitantly released NPY, may
reduce fear learning and decrease auditory responses in BLA principal
neurons (Fig. 4). Furthermore, neurogliaform cells and the related Ivy
cells are considered to be themost abundant types of interneurons in sev-
eral brain structures, including the cortex, hippocampus and interestingly
also the BLA (Fuentealba et al., 2008; Klausberger and Somogyi, 2008;
Manko et al., 2012). These neurons innervate the dendrites of pyramidal
neurons and evoke a slow GABAergic inhibition. Importantly,
neurogliaform and Ivy cells also contain considerable amounts of NPY. It
has been proposed that in the BLA these neurons form, more likely,
non-synaptic appositions than real synaptic contacts, indicating that
they may act via volume transmission releasing GABA and also NPY to
provide slow and diffuse inhibition of BLA network activity. It is thus con-
ceivable that upon emotional arousal, activation of neurogliaform and Ivy
cells may result in a reduction of fear expression during acquisition, recall
and fear extinction, an effect that may be even prolonged by concomitant
NPY release. Recent evidence suggests the additional presence of long-
range non-pyramidal NPY neurons in the LA and BLA projecting to the
basal forebrain (McDonald et al., 2012) and entorhinal cortex (Fig. 4)
(McDonald and Zaric, 2015a). On the other hand, a relatively small num-
ber of GABAergic, SST/NPY neurons in the amygdala-striatal transition
zone and in the entorhinal area are also targeting the BLA (Fig. 4)
(McDonald and Zaric, 2015b). The physiological relevance of these NPY
projection neurons is, however, still unclear. Taken together, NPY in the
BLA may predominantly originate from local interneurons (most of
them also contain SST) but also from afferent projections, and NPY is
also expressed in BLA efferent projections (Fig. 4).
4.1.2. NPY in the central amygdala (CEA)
The CEA, consisting of a lateral (CEl), medial (CEm) and capsular
(CEc) subdivision, is the main output nucleus of the amygdala and pro-
jects to the BNST, hypothalamus, basal forebrain and brain stem (Fig. 5)
(LeDoux et al., 1988). Ample evidence suggests that the CEA is most rel-
evant for fear expression. In fact, the CEA is far from being a passive out-
put relay, but forms in itself a highly elaborated micro-network and is
capable of establishing diverse forms of plasticity (Ciocchi et al., 2010;
Haubensak et al., 2010). In contrast to the BLA, the CEA is considered
to be a striatal-like structure (Fig. 3C–E) (McDonald, 1982a, 1982b).
Early studies have found that NPY is predominantly expressed in the
medial subdivision of the CEA, but only scattered neurons were found
in the CEc, and CEl. Most of the NPY neurons in the CEl did not co-
localize with SST (Gustafson, Card, & Moore, 1986; McDonald, 1989).
Furthermore, the NPY-IR in the CEm was predominantly originating
from local sources since different neurotoxic lesions of catecholaminer-
gic nuclei, such as the locus coeruleus and the ventral tegmental area
did not reduce NPY ﬁber staining in the CEm (Gustafson et al., 1986).
A recent study using NPY-GFP mice has demonstrated that NPY in
the CEA is contained in SST neurons and to a lesser extent in CR neurons,
in particular in the CEm (Wood et al., 2015). In the same study it has
been demonstrated that NPY neurons of the CEm connect also to the
BNST and vice versa, NPY neurons of the BNST project to the CEm.
Fig. 5. Schematic illustration of the main fear pathways with the expression of NPY, Y1 and Y2 receptors at different levels. Reciprocal connections between BLA and prefrontal cortex
(PL, prelimbic, IL, infralimbic) as well as hippocampus (HC) are important for fear expression, contextual modulation, and fear extinction allowing the transition between different fear states.
The central amygdala nucleus (CEA) initiates a fear response by projecting via the stria terminalis (st) and the bed nucleus of the stria terminalis (BNST) or directly to the periaqueductal gray
(PAG, causing a behavioral response), locus coeruleus (LC, arousal) and parabrachial nucleus (PBN, nociception), all of which are populated by NPY and Y receptor expressing neurons.
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(Im) (Fig. 2C), an amygdala cell cluster fundamentally involved in the
extinction of conditioned fear (Likhtik et al., 2008). In the Im, at least
two types of NPY neurons have been described (Fig. 4). Type one ex-
presses high levels of NPY and co-localizes with SST and type two co-
expresses dopamine D1 receptors (D1R) and has signiﬁcantly lower
levels of NPY, both on protein as well as on mRNA levels (Wood et al.,
2015). Thus, an extinction promoting effectmay bemediated byNPY re-
leased from D1R-expressing neurons of the Im targeting the CEm (Fig.
4). Indeed, recent evidence suggests that a marked increase in feed-
forward inhibition from the BLA to the CEm viamedioventral intercalat-
ed neurons is an electrophysiological correlate for the extinction of con-
ditioned fear (Amano et al., 2010; Verma et al., 2015c). It is tempting to
speculate that the lowbasal levels of NPY observed in D1R-positive neu-
rons of the Im can be up-regulated upon fear extinction learning and
thus represent a cornerstone for long-term suppression of fear. A central
role ofNPY in fear extinction is, however, supported by the complete ab-
sence of fear extinction in NPYKOmice (Verma et al., 2012). In this con-
text it is noteworthy that there are two additional brain areas with
similar NPY-expression patterns as observed in the Im: the reticular nu-
cleus of the thalamus (RT, Fig. 2B) (Morris, 1989) and the bed nucleus of
the anterior commissure (BAC, Fig. 2A), both consist of very dense accu-
mulations of NPY neurons that express considerably lower levels of NPY
than generally observed in NPY-neurons of the rest of the brain. Inter-
estingly, immunotoxin-mediated ablation of BAC neurons that exclu-
sively target the medial habenula resulted in higher fear responses
and increased fear memory (Yamaguchi et al., 2013). However, the
role of the dense accumulation of low-level NPY in these neurons re-
mains to be determined.
In summary, NPY in the amygdala cannot only modulate afferent
and efferent connections when released from local circuit neurons, but
NPY is also contained in afferent and efferent GABAergic projections ofthe amygdala (Fig. 4). Furthermore, NPY is involved in the micro-
network of inter-nuclear projections that connect different amygdala
nuclei or subdivisions of the same nucleus, some of which have been
identiﬁed as being central for fear extinction. Finally, there are several
brain regions with neurons expressing a relatively low level of NPY
with still unknown physiological relevance (Fig. 2).
4.2. Distribution of Y receptors in amygdala complex
Y1 receptors: In the amygdala complex, Y1 receptor mRNA has been
described in the BLA and LA as well as in the CEA (Fig. 1C). Immunohis-
tochemical data indicate that Y1 receptors are expressed by cell bodies
and dendrites (Kopp et al., 2002). A high concentration of Y1 receptor
protein was apparent in the LA and in particular in the CEm. Although
recent evidence suggests the expression of Y1 receptors in BLA pyrami-
dal neurons further studies are needed to reﬁne these ﬁndings
(Giesbrecht et al., 2010; Rostkowski et al., 2009). The identity of Y1 re-
ceptor expressing neurons in the CEA has not been addressed so far.
Y2 receptors: In the amygdala, Y2 receptors are predominantly
expressed in themedial subdivision of the central nucleus and in theme-
dial amygdala (Fig. 1E and F). Little expression has been observed in the
LA and BLA (Stanic et al., 2006). Similar to NPY, also Y2 receptors have
been described in the stria terminalis (Tasan et al., 2010). This indicates
that projections from the amygdala that target the BNST and other fore-
brain structures are also expressing Y2 receptors andmay be thus poten-
tially modulated along the whole extent of the stria terminals. Indeed,
local deletion of Y2 receptors in the central nucleus of the amygdala re-
sulted also in a reduction of [125I]PYY3-36 receptor binding in target
areas, such as BNST, nucleus accumbens shell and locus coeruleus (Tasan
et al., 2010). In the CEA, Y2 receptors are highly expressed in the medial
and in the capsular subdivisions but only weakly in the centrolateral
part (Stanic et al., 2006; Wood et al., 2015). Y2 receptor-expressing
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NPY as shown by dual-immunohistochemistry in colchicine treated
mice (Stanic et al., 2011). In a recent study, expression of Y2 receptors
was also apparent in intercalated neurons of the amygdala. In particular,
Y2 receptor labeling was demonstrated between the BLA and CEA
connecting there the dorsomedial cluster of the intercalated neurons
with the main intercalated nucleus (Wood et al., 2015). This connection
between different ITC clusters has been implicated in fear extinction pre-
viously (Pare et al., 2004) and NPYmay have a supportive role by activa-
tion of Y2 receptors. Thus, Y2 receptors are expressed along ﬁber tracts of
the extended amygdala (Fig. 4) and their putative presynaptic localiza-
tion may reduce the frequency of neurotransmitter release and dampen
network activity (discussed in detail below). Importantly, Y2 receptors
in the amygdala did not co-localize with NPY neurons (Stanic et al.,
2011; Wood et al., 2015) precluding a direct release-inhibiting activity
on NPY neurons. Y2 receptors may rather function as hetero-receptors
on long-ﬁber tracts and NPYmay be released from adjacent interneurons
upon strong and repetitive stimulations. Thus, a Y2 receptor-dependent
effect will be apparent under stressful conditions and volume transmis-
sion of NPY may produce a long-lasting inhibition.
4.3. Electrophysiology of NPY in the extended amygdala
The amygdala complex consists of various nuclei with a predomi-
nantly unidirectional information-ﬂow from the LA and BLA nuclei as
major input stations to the CEA as a major output (Fig. 3B). Because of
their high similarity in terms of neuronal populations and connectivity,
the CEA, the BNST, substantia inominata and the nucleus accumbens shell
are summarized as the so-called extended amygdala. As mentioned
above, the CEA and BNST are reciprocally connected independently by
NPY and Y2 receptor containing neurons providing a framework for
the modulation of synaptic activity (Fig. 5).
Bed nucleus of the stria terminalis: Recent studies utilizing stimula-
tions of speciﬁc projections by optogenetics have demonstrated that
the BNST and its projections to several brain regions play a critical role
in modulating speciﬁc physiological aspects of fear and anxiety
(Jennings et al., 2013; Kim et al., 2013). It is well known that NPY and
NPY receptors are expressed in the BNST and stria terminalis (Kash
and Winder, 2006; Tasan et al., 2010; Wood et al., 2015) and are thus
well positioned to modify fear and anxiety.
Consistent with the ﬁnding that NPY reduces excitatory and inhibi-
tory synaptic transmission in the hippocampus, often by presynaptic
Y2 receptors and reduced presynaptic calcium inﬂux (see Electrophysi-
ology in the Hippocampus below), activation of the Y2 receptor in the
BNST suppresses GABAergic transmission by a similar mechanism
(Kash andWinder, 2006; McCall et al., 2013). Using the Y2 receptor ag-
onist and antagonist, NPY13-36 and BIIE0246, respectively, Kash and
Winder (2006) demonstrated that Y2 receptor activation reduces the
amplitude of evoked inhibitory postsynaptic currents in ventrolateral
BNST neurons while Y1 and Y5 receptor agonists and antagonists had
no effect. Interestingly, chronic stress reduces the ability of NPY to sup-
press evoked inhibitory postsynaptic currents in DBA/2Jmice, but not in
C57BL/6J mice, suggesting that stress can alter NPY signaling and that
this may depend on genetic background (Pleil et al., 2012). Postsynaptic
NPY receptors have also been detected in the BNST. Speciﬁcally, NPY
causes hyperpolarization of the resting membrane potential in a subset
of dorsolateral BNST neurons by blocking the hyperpolarization-
activated current (Ih): an effect blocked by co-application of the Y1
and Y5 receptor antagonists, BIBP-3226 and L-152,804, respectively
(Ide et al., 2013). Although many studies have found that NPY typically
reduces synaptic transmission, it is interesting to note that NPY can also
enhance inhibitory transmission. Pleil et al. (2015) demonstrated that
the Y1 receptor agonist, Leu31Pro34 NPY increases the frequency of
miniature inhibitory postsynaptic currents in BNST neurons probably
by increasing the surface expression of postsynaptic GABAA receptors
(Pleil et al., 2015).Although relatively few studies have investigated the effects of NPY
in the BNST, it is clear that NPY may cause a decrease or increase in in-
hibitory input to BNST neurons depending on whether NPY activates
pre- or postsynaptic receptors, respectively. Identifying the neuronal
populations that are modulated by Y1 and Y2 receptors and under-
standing the following downstream projections and their relevance
for fear expression may shed more light on the role of NPY in the BNST.
Central amygdala: Moving to the central amygdala, Gilpin et al.
(2011) found that while ethanol increases inhibitory transmission by
increasing presynaptic GABA release probability, this could be occluded
by NPY-mediated activation of the Y2 receptor (Gilpin et al., 2011). In-
terestingly, application of the Y2 receptor antagonist, BIIE0246, in-
creased the amplitude of evoked inhibitory postsynaptic potentials but
NPY application did not modify miniature inhibitory postsynaptic cur-
rents, together suggesting that NPY may tonically inhibit GABAergic
transmission in the central amygdala. On the other hand, Wood et al.
(2015) found that the Y2 receptor agonist, PYY3-36, reduces the frequen-
cy of both spontaneous inhibitory and excitatory postsynaptic currents
in neurons speciﬁcally in themedial subdivision of the central amygdala
(CEm) and that NPY- and Y2 receptor knockout mice exhibit elevated
inhibitory transmission. These latter results are consistent with a tonic
activation of Y2 receptors on GABAergic synapses targeting neurons of
the CEm, however, application of the Y2 receptor antagonist, JNJ
31020028, did not increase inhibitory neurotransmission, suggesting
an important role for NPY receptors during development. Evoked inhib-
itory postsynaptic currents in response to electrical stimulation of the
medial input to the CEm, likely arising from the BNST, were attenuated
by PYY3-36, providing evidence that BNST projections to the CEm ex-
press the Y2 receptor. Although, at ﬁrst glance, the studies by Gilpin
et al. (2011) and Wood et al. (2015) may appear to have opposing re-
sults, the differences observed are probably due to differences in cell se-
lection for recordings or time of day that they were performed (i.e., CEA
versus CEm, and dark versus light phase, respectively). Regardless, these
studies provide evidence that NPY signaling, particularly via the Y2 re-
ceptor, modiﬁes synaptic transmission in the central amygdala and
may present a therapeutic target in the treatment of anxiety and fear-
related disorders.
Basolateral amygdala: Although the BLA is essential for fear learning
and contains considerable amounts of NPY and Y receptors, only a hand-
ful of studies have investigated how NPY inﬂuences neurotransmission
in the BLA using electrophysiological recordings. These studies provide
important insights into how NPY signaling alters BLA function and fear
processing. As in the other brain regions discussed, NPY signaling via
the Y1 receptor leads to a reduction in intrinsic excitability of neurons
in the BLA. Sosulina et al. (2008) found that, speciﬁcally in the lateral
amygdala, NPY application activated Y1 receptor-coupled G protein-
coupled inwardly-rectifying potassium (GIRK) channels causing hyper-
polarization of the resting membrane potential and attenuated action
potential ﬁring (Sosulina et al., 2008). Similar results have been report-
ed, more generally, in the BLA, where NPY hyperpolarizes the resting
membrane potential of pyramidal neurons and decreases their intrinsic
excitability (detected by an increase in rheobase, i.e., the minimal
amount of current required to evoke action potentials (Giesbrecht
et al., 2010)). The effect of NPY was replicated using the Y1 receptor-
selective agonist, F7P34NPY, andwas blocked by the Y1 receptor antag-
onist, BIBO3304. Similar to ﬁndings in the BNST, the effect of NPY was
attributable to suppression of a tonic hyperpolarization-activated cur-
rent (Ih). As would be expected, NPY can dampen network activity in
the BLA as compound postsynaptic potentials (generated using a high-
potassium model) are attenuated by NPY (Chung and Moore, 2009).
The Y1 receptor has also been shown to alter excitatory and inhibi-
tory synaptic transmission in BLA pyramidal neurons. Speciﬁcally, acti-
vation of Gi/o-coupled Y1 receptors reduces NMDA receptor-mediated
excitatory postsynaptic currents and increases GABAA receptor-
mediated inhibitory postsynaptic currents by reducing the activity of
exchange protein activated by cAMP (Epac) and Protein Kinase A
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the Y1 receptor was also found to increase GABAA receptor-mediated
inhibition in the BNST (Pleil et al., 2015), as this provides a ﬁne example
of the similarities in Y receptor function in different brain regions. Thus,
these studies provide evidence that NPY likely exerts its potent fear-
reducing effects when injected into the BLA by reducing the activity of
BLA pyramidal neurons.
4.4. Distribution and connectivity of NPY neurons in the hippocampus
GABA/NPY interneurons are abundant in all parts of the hippocam-
pal formation, including the dentate gyrus, sectors CA1 to CA3 of the
hippocampus proper, the subiculum and the entorhinal cortex (Kohler
et al., 1986; Morris, 1989). They display extensive co-localization with
SST and form symmetric synapses on dendrites of pyramidal neurons
(Kohler et al., 1987). In the dentate gyrus, NPY is expressed by multiple
classes of morphologically distinct dentate interneurons and potentially
also in dentate granule cells where NPY is up-regulated following epi-
leptic seizures (Deller and Leranth, 1990; Sperk et al., 2007). Themajor-
ity of NPY neurons of the dentate hilus are medium-sized multipolar
and fusiform cells. They co-express SST and send their axons to granule
cell dendrites in the outer molecular layer (Kohler et al., 1987; Kosaka
et al., 1988). A second population of NPY interneurons comprises pyra-
midal shaped cells at the inner surface of the granule cell layerwith long
apical dendrites reaching also the outer molecular layer. Some small
multipolar NPY-IR cells are located in the molecular layer (Deller and
Leranth, 1990; Kohler et al., 1986). In the rat, about 2% of the NPY neu-
rons also project to the contralateral dentate gyrus (Deller and Leranth,
1990). The main target cells of NPY neurons are, however, probably ip-
silateral dentate granule cells on which they may exert a dendritic Y1
receptor- and an axonal Y2 receptor-mediated inhibition. Furthermore,
NPY neurons are also targeting neurons located in the hilus. In the den-
tate gyrus, synaptic inputs to NPY neuronsmay originate from different
sources, such as the entorhinal and commissural inputs andmossy ﬁber
collaterals from dentate granule cells. Also extra-hippocampal projec-
tions from cholinergic neurons of the medial septum are targeting
NPY neurons of the dentate gyrus (Milner et al., 1997, 1999). In CA3
and CA1, inputs to NPY neurons may originate from mossy ﬁbers and
Schaffer collaterals or the entorhinal cortex, respectively.
4.5. Distribution and connectivity of Y receptors in the hippocampus
Y1 receptors: The highest amounts of Y1 receptors are present on
dentate granule cells with somewhat lower expression in the pyramidal
cell layer of the CA regions and probably also on scattered interneurons
of the strata oriens and radiatum. Immunohistochemical data suggest a
predominantly postsynaptic expression of Y1 receptors in the hippo-
campus, supported by dendritic labeling of the molecular layer of the
dentate gyrus and strata oriens and radiatum of the hippocampus proper
(Dumont et al., 1996; Kopp et al., 2002). This is also corroborated by
comparing in situ hybridization data and receptor binding using Y1 re-
ceptor selective ligands (Fig. 1C and D) (Dumont et al., 1996; Gobbi
et al., 1998; Koﬂer et al., 1997; Larsen et al., 1993).
Y2 receptors: Y2 receptor mRNA containing somata are predomi-
nately located in the granule cell layer of the dentate gyrus and in the
pyramidal cell layer of the CA regions (Gustafson et al., 1997). On the
other hand, Y2 receptor immunoreactivity and Y2 receptor binding is
apparent in the strata radiatum, oriens and lucidum as well as in the
hilus of the dentate gyrus (Dumont et al., 1996; Schwarzer et al.,
1998; Stanic et al., 2006). Interestingly, dense Y2 receptor immuno-
labeling has been described in the granule cell layer of the ventral but
not of the dorsal hippocampus (Stanic et al., 2006). The discrepancy be-
tween the distribution of Y2 receptormRNAandY2 receptor IR/receptor
binding strongly supports a predominantly presynaptic localization of
Y2 receptorswithin the hippocampal formation (Fig. 1E and F). Further-
more, since Y2 receptors seem to be present on glutamatergic principalneurons, release of NPYmay result in a signiﬁcant reduction of synaptic
transmission in the tri-synaptic hippocampal pathway (Colmers et al.,
1991). It iswell known that hippocampal activity is correlatedwith con-
textual memory formation (Maren et al., 2013). Dentate granule cells
are usually strongly inhibited and only a speciﬁc ensemble becomes ac-
tivated upon encoding of new memories (Chawla et al., 2005; O'Keefe
and Nadel, 1978). Recently, it has been suggested that newly born neu-
rons of the dentate gyrus are essential for discriminative learning in a
contextual fear conditioning task (Aimone et al., 2010). This is interest-
ing in light of impaired fear discrimination in Y2KO mice (Verma et al.,
2012) as it suggests that Y2 receptors may increase the contrast of syn-
aptic encoding by inhibiting granule cell ﬁring frequency in the mossy
ﬁber pathway. Whether Y2 receptors are absent from newly born neu-
rons, selectively increasing their activity and resulting in improved pat-
tern separation remains to be demonstrated.
4.6. Electrophysiology of neuropeptide Y in the hippocampus
Solid evidence supports the role of the hippocampus in contextual
fear learning (Ji and Maren, 2007; Maren et al., 2013). As discussed
above, a few studies have investigated howmodifying NPY signaling al-
ters contextual fear memory, but none has directly targeted the hippo-
campus or combined electrophysiological analysis to investigate how
synaptic transmission was altered. This is of course a big drawback con-
sidering the high expression of NPY itself and the even higher expres-
sion of the respective Y receptors in this brain area (Fig. 1). However,
one can speculate as to how NPY signaling modiﬁes fear processing in
the hippocampus based upon the numerous studies characterizing
how NPY modiﬁes synaptic transmission in the different hippocampal
subﬁelds.
In fact, many of the initial studies to describe how NPY inﬂuences
synaptic transmissionwere performed in the hippocampus. These stud-
ies demonstrated that NPY modulates synaptic transmission in the hip-
pocampus at each level of the tri-synaptic loop: entorhinal cortex input
to the dentate gyrus, dentate gyrus to CA3, CA3 to CA1 and subiculum. In
general, electrophysiological recordings obtained from in vitro brain
slice preparations from rodents and resected human tissue, have consis-
tently found that bath application of NPY leads to a decrease in synaptic
transmission via a presynaptic mechanism (Haas et al., 1987; Klapstein
and Colmers, 1993). In region CA1 and CA3, NPY activates Y2 receptors
that reduce glutamate release probability by limiting presynaptic inﬂux
of calcium ions via N and P/Q-type voltage dependent calcium channels
(Colmers et al., 1987, 1988; El Bahh et al., 2005; Klapstein and Colmers,
1993; Qian et al., 1997; Sun andMiller, 1999;Weiser et al., 2000). Lower
levels of calcium inﬂux attenuate evoked excitatory postsynaptic poten-
tials, and decrease the frequency of spontaneous excitatory postsynap-
tic currents to pyramidal neurons (McQuiston and Colmers, 1996).
Thus, NPY signaling in the CA1 and CA3 regions signiﬁcantly modiﬁes
particularly excitatory neurotransmission and can thereby inﬂuence
synaptic plasticity. Sorensen et al. (2008a, 2008b) demonstrated that
transgene expression of NPY in the hippocampus impairs long-term po-
tentiation (LTP, a type of synaptic plasticity critical for learning and
memory) at both Schaffer collateral-CA1 synapses and CA1-subiculum
synapses, and impairs performance in the two-platform spatial discrim-
ination water maze designed to assess hippocampal function. Further-
more, exogenous application of NPY prior to tetanic stimulation (high
frequency stimulation used to induce LTP) blocks LTP induction by acti-
vating the Y2 receptor, and NPY administered severalminutes after suc-
cessful LTP induction attenuates evoked excitatory postsynaptic
potentials back to baseline levels (Sorensen et al., 2008a, 2008b).
Excitatory synaptic transmission at mossy ﬁber-CA3 synapses is also
attenuated by NPY application (Klapstein and Colmers, 1993). Guo et al.
(2002) observed that NPY, the Y1 agonist Leu31Pro34 NPY, the Y2 ago-
nist NPY13-36 and the Y5 receptor-preferring agonist D-Trp32 NPY all de-
creased the amplitude of ﬁeld excitatory postsynaptic potentials in
region CA3 (evoked by electrical stimulation of the mossy ﬁber
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patients and in an animal model of epilepsy, Y1 receptor binding was
signiﬁcantly reduced (Furtinger et al., 2001; Koﬂer et al., 1997), suggest-
ing rapid down-regulation upon repetitive, strong neuronal excitation,
presumably by receptor internalization. The role of Y1 receptors in hip-
pocampal circuitries is, however, poorly understood. Taken together,
these studies provide a detailed characterization of howNPY alters syn-
aptic transmission in region CA1 and CA3, particularly via the Y2 recep-
tor, and shed light on how changes in synaptic transmission modify
learning and memory.
Within the dentate gyrus, inhibitory cholecystokinin (CCK)-expressing
basket cells, known to play a central role in generating γ-frequency
oscillations (Freund, 2003), exhibit a reduction of excitatory and inhibitory
input in response to NPY application in vitro. Ledri et al. (2011; 2012)
found that NPY, via Y2 receptors, reduced the frequency of both excitatory
and inhibitory postsynaptic currents in CCK-expressing basket cells,
however, NPY treatment did not alter the intrinsic membrane properties
(e.g., restingmembranepotential, rheobase or action potential characteris-
tics) of the basket cells, suggesting that CCK-expressing basket cells do not
express postsynaptic NPY receptors but rather receive excitatory and
inhibitory input from synapses containing functional Y2 receptors
(Ledri et al., 2011, 2012). Interestingly, in mice subjected to repetitive
seizures, NPY acted preferentially on synapses targeting the peri-somatic
region of CCK-expressing basket cells, rather than more distant dendritic
synapses, detected by speciﬁc changes in event kinetics. Thus, given the
central role of CCK-expressing basket cells in governing network
oscillations, the localization of NPY receptors along the somatodendritic
axis of CCK-expressing basket cells may allow ﬁne-tuning of network
activity from the dentate gyrus to its postsynaptic targets.
Inhibitory hilar neurons extend their axons to the molecular layer
where they modulate excitatory synaptic transmission from the
perforant path to the granule cell layer of the dentate gyrus. Hilar neu-
rons express postsynaptic Y1 receptors and activation of the Y1 receptor
enhances the activity of GIRK channels, leading to membrane hyperpo-
larization and a reduction in spike frequency (Fu and van den Pol, 2007;
Paredes et al., 2003). Interestingly, GABAmay act excitatory in hilar NPY
neurons of the mouse (Fu and van den Pol, 2007), potentially resulting
in rapid synchronization of GABA, SST and NPY release and profound
pre- and postsynaptic inhibition of excitatory hippocampal circuits.
Importantly, resected brain tissue taken from epileptic patients has
provided evidence that NPY reduces excitatory transmission in the den-
tate gyrus and region CA1, via Y2 receptors, also in the human brain
(Ledri et al., 2015; Patrylo et al., 1999). Furthermore, expression of
NPY aswell as Y1 and Y2 receptors undergo considerable plastic chang-
es in the dentate gyrus and subiculum in animal models of epilepsy and
in human tissue obtained by temporal lobe epilepsy surgery (Furtinger
et al., 2001; Vezzani and Sperk, 2004).
Taken altogether, these studies show that NPY signaling has a prom-
inent role in the hippocampus. Thus, pharmacological interventions of
the NPY system here, using speciﬁc agonists and antagonists, could be
used to alter hippocampal function thereby modifying learning and
memory, possibly in relation to fear and anxiety disorders.
Considering the electrophysiological data obtained in the central ex-
tended amygdala, BLA and hippocampus altogether, it is tempting to
conclude that the role of NPY is to reduce the activity of neurons. Broad-
ly speaking, this is accomplished by presynaptic Y2 receptors that re-
duce excitatory transmission, and/or by postsynaptic Y1 receptors that
reduce intrinsic excitability. However, a more complex situation exists
whereby the hallmark NPY-mediated reduction of excitability is ob-
served primarily in excitatory principal neurons, whereas NPY can in-
crease inhibition, as observed in the BLA and BNST, or decrease
inhibition, with or without a concomitant reduction in excitatory
input, as observed in CCK-expressing basket cells in the hippocampus
and GABAergic neurons in central extended amygdala. Furthermore,
the functions of the Y4 and Y5 receptor are still poorly characterized.
Thus, when considering therapeutic approaches that aim to modifyfear processing by altering neurotransmission by NPY signaling, Y re-
ceptor distribution (i.e., pre- versus postsynaptic, excitatory versus in-
hibitory neurons) is an important consideration.5. Conclusions and future directions
As outlined in this review, NPYmodulates fearwith a strong tendency
towards reducing fear expression. Furthermore, NPY facilitates cued and
contextual fear extinction, within-session and also the retrieval of extinc-
tion. Not surprisingly, it was suggested that these effects are generated in
the BLA and CEA, two hotspots of fear processing. Since Y1 receptors are
predominantly mediating the anxiolytic responses of NPY, they have
been primarily addressed in models of learned fear. In the BLA, NPY co-
localizes mostly with SST and hyperpolarizes principal neurons decreas-
ing their intrinsic excitability by a Y1 receptor-mediated mechanism.
Whether these NPY/SST neurons are reducing fear responses by
inhibiting pyramidal neurons via direct synaptic contacts or if they are
generally dampening synaptic activity by volume transmission, as sug-
gested for the neurogliaform/Ivy cell groups, remains to bedemonstrated.
It seems, however, that fear and fear extinction rely also on other Y recep-
tors that are acting synergistically with Y1 receptors. In particular, Y2 and
also Y4 receptors are both involved in the extinction of fear. This may
have important implications when developing novel therapeutic con-
cepts for treating anxiety disorders, putting agonists and not antagonists
for Y2 and Y4 receptors into focus. Given the general paucity of Y1 recep-
tor expression in the human brain contrastingwith high expression of Y2
receptors in the human cerebral cortex, a central role of Y2 receptors be-
comes more and more apparent when trying to translate experimental
data from bench to bedside. Since Y2 receptors in the CEAmay reduce in-
hibitory andexcitatory synaptic transmission, characterization of the syn-
aptic inputs and identiﬁcation of the respective target neurons will
increase our understanding of the involvedmicrocircuits. From the avail-
able data it becomes clear that NPYmodulates the fear circuitry at multi-
ple successive access points, including the main intercalated nucleus,
with its dense accumulation of NPY neurons, and the CEA with its recip-
rocal connections to the BNST. However, the role of Y1 receptors in the
CEA or Y2 receptors in the BNST in fear conditioning and extinction as
well as the underlying electrophysiological responses have not been in-
vestigated so far. Furthermore, while Y5 receptors have been proposed
as possible modulators of conditioned fear, experimental evidence is
not yet available. Behavioral and electrophysiological evidence of how
NPY modiﬁes the fear circuit is largely based on exogenous NPY applica-
tion, leaving the role of endogenous NPY still open. Furthermore, addi-
tional studies are required to provide an overall concept of how NPY
regulates amygdala activity at the level of microcircuits and to delineate
the role of other brain areas, such as the hippocampus and cortical
areas, all in relation to fear and fear extinction.Conﬂict of interest
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